Protagonist Therapeutics, Inc. (PTGX) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
PTGX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PTGX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.3% | -343.6% | -282.8% |
| 2024 | 100.0% | 58.2% | 63.3% |
| 2023 | 100.0% | -156.1% | -131.6% |
| 2022 | 100.0% | -494.2% | -479.3% |
| 2021 | 100.0% | -460.0% | -458.9% |
Download Data
Export PTGX earnings history in CSV or JSON format
Free sign-in required to download data
Protagonist Therapeutics, Inc. (PTGX) Earnings Overview
As of May 7, 2026, Protagonist Therapeutics, Inc. (PTGX) reported trailing twelve-month net income of -$115M, reflecting -148.5% year-over-year growth. The company earned $-1.63 per diluted share over the past four quarters, with a net profit margin of -282.8%.
Looking at the long-term picture, PTGX's historical earnings data spans multiple years. The company achieved its highest annual net income of $275M in fiscal 2024.
Protagonist Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), KYMR (-$315M net income, -794.4% margin), PRTA (-$244M net income, -2520.6% margin), PTGX has comparable earnings metrics. Compare PTGX vs IMVT →
PTGX Earnings vs Peers
Earnings metrics vs comparable public companies
PTGX Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$130M | -147.3% | -$158M | $-2.05 | -282.8% | -343.6% |
| 2024 | $275M | +448.5% | $253M | $4.23 | 63.3% | 58.2% |
| 2023 | -$79M | +38.0% | -$94M | $-1.39 | -131.6% | -156.1% |
| 2022 | -$127M | -1.5% | -$131M | $-2.52 | -479.3% | -494.2% |
| 2021 | -$126M | -89.8% | -$126M | $-2.65 | -458.9% | -460.0% |
| 2020 | -$66M | +14.3% | -$65M | $-1.92 | -231.1% | -225.4% |
| 2019 | -$77M | -98.3% | -$81M | $-2.98 | -33414.3% | -34857.6% |
| 2018 | -$39M | -5.3% | -$42M | $-1.74 | -125.9% | -136.7% |
| 2017 | -$37M | +0.6% | -$38M | $-2.09 | -184.2% | -188.9% |
| 2016 | -$37M | -150.2% | -$33M | $-5.72 | - | - |
See PTGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTGX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTGX — Frequently Asked Questions
Quick answers to the most common questions about buying PTGX stock.
Is PTGX growing earnings?
PTGX EPS fell to $-1.63, with earnings declining -148.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-115M.
What are PTGX's profit margins?
Protagonist Therapeutics, Inc. net margin is -282.8%, with operating margin at -343.6%. Below-average margins reflect competitive or cost pressures.
How consistent are PTGX's earnings?
PTGX earnings data spans 2014-2025. The declining earnings trend is -148.5% YoY. Historical data enables comparison across business cycles.